SCHEMBL3955263

SCHEMBL3955263

O=C(CO)C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
EPHX1 P07099 6/20 0.41
HSD11B1 P28845 3/20 0.38
RECQL P46063 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.35
HSD11B2 P80365 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NAAA Q02083 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
EPHX2 P34913 1/20 0.35
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443541 1.00 CES2 (0.52) CES2CES1HDAC8HDAC6TSHR
SCHEMBL5456066 0.97
SCHEMBL5456064 0.97
SCHEMBL873747 0.92
SCHEMBL5415862 0.85
SCHEMBL1088091 0.81 CES2 (0.50) CES2CES1HDAC8HDAC6TSHR
SCHEMBL28425729 0.80 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR
SCHEMBL29333093 0.80 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR
SCHEMBL29333109 0.80 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR
SCHEMBL599277 0.80 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107986943-B Synthesis method of cyclohexanedimethanol, catalyst and application thereof 万华化学集团股份有限公司 2021-04-20 CN claimed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US claimed
US-6979686-B1 Substituted pyrazoles as p38 kinase inhibitors PHARMACIA CORPORATION (US) 2005-12-27 US claimed
EP-1144403-B1 SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS SEARLE LLC (US) 2004-10-06 EP claimed
US-6525059-B1 Mitogen-activated protein kinases (MAP); G. D. SEARLE & COMPANY 2003-02-25 US claimed
EP-1144403-A1 SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2001-10-17 EP claimed
WO-2000031063-A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2000-06-02 WO claimed
CN-114231507-B Choline Arthrobacter choline oxidase mutant and application thereof 无锡阿科力科技股份有限公司 2023-11-14 CN disclosed
CN-114231507-A Choline oxidase mutant of Arthrobacter bilis and application thereof 无锡阿科力科技股份有限公司 2022-03-25 CN disclosed
CN-107986943-B Synthesis method of cyclohexanedimethanol, catalyst and application thereof 万华化学集团股份有限公司 2021-04-20 CN disclosed
US-20180079823-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2018-03-22 US disclosed
US-20170183419-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-06-29 US disclosed
EP-2051955-B1 PRODUCTION OF ALPHA HYDROXY KETONES VIA CARBENE CATALYZED POLE REVERSAL REACTION OF ALDEHYDES EVONIK DEGUSSA GMBH (DE) 2016-08-31 EP disclosed
US-4061851-A 7-Amino-7-arylthio cephalosporins E. R. SQUIBB & SONS, INC. (US) 1977-12-06 US disclosed
US-4061629-A 6-Amino-6-arylthio penicillanic acids and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1977-12-06 US disclosed
US-4029669-A 6-Benzalimino-6-arylthio penicillanic acids and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1977-06-14 US disclosed
US-4026886-A 7-Acyl-7-arylthiocephalosporins E. R. SQUIBB & SONS, INC. (US) 1977-05-31 US disclosed
US-3994912-A INTERMEDIATES E. R. SQUIBB & SONS, INC. (US) 1976-11-30 US disclosed
US-3965093-A 6-Arylthio penicillanic acid and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1976-06-22 US disclosed
US-3954744-A ANTIBACTERIAL E. R. SQUIBB & SONS, INC. (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 CES2 4820/4885CES1 3698/4885HDAC8 357/4885
US-20170183419-A1 NOVEL BENZODIAZEPINE DERIVATIVES GABRB1, GABRB3, GABRA1 CES2 1717/4885CES1 1385/4885HDAC8 1313/4885
US-20180079823-A1 NOVEL BENZODIAZEPINE DERIVATIVES GABRB1, GABRB3, GABRA1 CES2 1717/4885CES1 1385/4885HDAC8 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.